The true-positive rate of 64% emphasizes the patients who derive the most benefit from WB-MRI screening—those patients with LFS, MEN1, and VHL, whose cancers were found at an early, nonmetastatic stage and were treated with curative intent via surgery and systemic therapy. The gene discussed is VHL; the disease is cancer.